In a report released today, Sachin Jain from Bank of America Securities reiterated a Buy rating on Sanofi, with a price target of €102.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sachin Jain’s rating is based on several key factors. Primarily, the Buy rating is driven by the valuation of Sanofi’s stock, which is currently seen as undervalued with a price-to-earnings ratio of approximately 11 times the expected earnings in 2027. This valuation is attractive given the anticipated compound annual growth rate of 13% in earnings per share from 2027 to 2030, which is largely supported by the company’s earnings projections for 2026 and 2027.
Despite a lack of significant catalysts in the next 12 months, Jain sees potential in upcoming data releases and product launches, such as amlitelimab and tolebrutinib, which could positively impact investor sentiment. There are some risks, notably the uncertainty surrounding the approval of tolebrutinib for secondary progressive multiple sclerosis, but these are considered manageable. Additionally, the company’s expected sales and earnings growth for 2026 are in line with or slightly above consensus estimates, further supporting the Buy recommendation.
In another report released on November 25, Deutsche Bank also maintained a Buy rating on the stock with a €110.00 price target.